Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy
Based on Medicare claims data, most patients diagnosed with ATTRwt-CM have not been diagnosed following consensus-recommended pathways.
Authors
- Ronald Witteles (ORCID: https://orcid.org/0000-0002-3043-1472)
- Abbas Ebrahim (ORCID: https://orcid.org/0000-0002-8100-9677)
- Haechung Chung (ORCID: https://orcid.org/0000-0001-9486-3824)
- Andrew Rava
- Cindi Pankratova
- Feng Dai
- Cynthia Gutierrez
- Sameer Swarup
Institutions
- Pfizer (United States) (US)
- Stanford Medicine (US)
- Public Health Solutions (US)
- Stanford University (US)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fcvm.2025.1638380
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer